CBX-12 for children and young adults with hard-to-treat solid tumors
Part of Cancer clinical trials.
This trial studies a new experimental drug called CBX-12 for children, teens, and young adults with solid tumors that have returned or are hard to treat. The drug is designed to target and kill cancer cells, and the study will find the best dose and see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age: between 1 and 30 years old
- Has a solid tumor (not brain or spinal) that has come back or is hard to treat
- Tumor must be measurable (Part B) or at least evaluable (Part A)
- No prior treatment with exatecan or deruxtecan-based drugs, and no progression while on TOP1 inhibitors like irinotecan
- No active cancer spread to the brain or spinal cord
- Good kidney, liver, and bone marrow function (as shown by blood tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
This study is testing new drugs for young people (ages 10 and up) with Ewing sarcoma or related tumors that have come back or stopped responding to treatment. The goal is to find promising drugs that may help shrink tumors or slow their growth.
This trial tests a new drug called CBX-663 in people with certain blood cancers, solid tumors, or glioblastoma that have returned or not responded to standard treatment. It aims to see if the drug is safe and helps shrink or control the cancer.
Hear when a new Refractory Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.